Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
Oncologist. 2023 Mar 17;28(3):e167-e170. doi: 10.1093/oncolo/oyac255.
In phase III TIVO-3 trial, tivozanib improved progression-free survival (PFS) compared to sorafenib for patients with metastatic renal cell carcinoma (mRCC). However, the effectiveness of this drug after exposure to other selective VEGFR agents has not yet been defined. Herein, we characterize the clinical efficacy of tivozanib in patients with mRCC previously treated with axitinib.
We identified patients from the intention to treat (ITT) population, in the TIVO-3 trial, who received treatment with axitinib before enrolment in the study and evaluated PFS, response rate (RR), and safety.
Out of 350 patients, 172 (83:89, tivozanib:sorafenib) had received prior treatment with axitinib in TIVO-3. In this subgroup, PFS was 5.5 months with tivozanib and 3.7 months with sorafenib (HR 0.68). RR was 13% and 8% favoring tivozanib.
Tivozanib is active in the treatment of patients with mRCC who have progressed on prior therapies, including axitinib.
在 III 期 TIVO-3 试验中，与索拉非尼相比，替沃扎尼可改善转移性肾细胞癌（mRCC）患者的无进展生存期（PFS）。然而，尚未确定该药物在接触其他选择性 VEGFR 药物后的有效性。在此，我们描述了先前接受阿昔替尼治疗的 mRCC 患者使用替沃扎尼的临床疗效。
我们从 TIVO-3 试验的意向治疗（ITT）人群中确定了接受阿昔替尼治疗后入组研究的患者，并评估了 PFS、缓解率（RR）和安全性。
在 350 名患者中，172 名（83：89，替沃扎尼：索拉非尼）在 TIVO-3 中接受了阿昔替尼的预先治疗。在该亚组中，替沃扎尼的 PFS 为 5.5 个月，索拉非尼为 3.7 个月（HR 0.68）。RR 分别为 13%和 8%，替沃扎尼更具优势。
替沃扎尼在治疗先前治疗进展的 mRCC 患者中具有活性，包括阿昔替尼。
Zotero 插件